Low-Density Lipoprotein Receptor (LDLR) Is Involved in Internalization of Lentiviral Particles Pseudotyped with SARS-CoV-2 Spike Protein in Ocular Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Jul 2023
Historique:
received: 19 05 2023
revised: 16 07 2023
accepted: 17 07 2023
medline: 31 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Here, we present evidence that caveolae-mediated endocytosis using LDLR is the pathway for SARS-CoV-2 virus internalization in the ocular cell line ARPE-19. Firstly, we found that, while Angiotensin-converting enzyme 2 (ACE2) is expressed in these cells, blocking ACE2 by antibody treatment did not prevent infection by SARS-CoV-2 spike pseudovirions, nor did antibody blockade of extracellular vimentin and other cholesterol-rich lipid raft proteins. Next, we implicated the role of cholesterol homeostasis in infection by showing that incubating cells with different cyclodextrins and oxysterol 25-hydroxycholesterol (25-HC) inhibits pseudovirion infection of ARPE-19. However, the effect of 25-HC is likely not via cholesterol biosynthesis, as incubation with lovastatin did not appreciably affect infection. Additionally, is it not likely to be an agonistic effect of 25-HC on LXR receptors, as the LXR agonist GW3965 had no significant effect on infection of ARPE-19 cells at up to 5 μM GW3965. We probed the role of endocytic pathways but determined that clathrin-dependent and flotillin-dependent rafts were not involved. Furthermore, 20 µM chlorpromazine, an inhibitor of clathrin-mediated endocytosis (CME), also had little effect. In contrast, anti-dynamin I/II antibodies blocked the entry of SARS-CoV-2 spike pseudovirions, as did dynasore, a noncompetitive inhibitor of dynamin GTPase activity. Additionally, anti-caveolin-1 antibodies significantly blocked spike pseudotyped lentiviral infection of ARPE-19. However, nystatin, a classic inhibitor of caveolae-dependent endocytosis, did not affect infection while indomethacin inhibited only at 10 µM at the 48 h time point. Finally, we found that anti-LDLR antibodies block pseudovirion infection to a similar degree as anti-caveolin-1 and anti-dynamin I/II antibodies, while transfection with LDLR-specific siRNA led to a decrease in spike pseudotyped lentiviral infection, compared to scrambled control siRNAs. Thus, we conclude that SARS-CoV-2 spike pseudovirion infection in ARPE-19 cells is a dynamin-dependent process that is primarily mediated by LDLR.

Identifiants

pubmed: 37511618
pii: ijms241411860
doi: 10.3390/ijms241411860
pmc: PMC10380832
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Cholesterol 97C5T2UQ7J
Clathrin 0
Dynamin II EC 3.6.5.5
GW 3965 0
Lipoproteins, LDL 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
LDLR protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NEI NIH HHS
ID : Intramural Research Program
Pays : United States

Références

Methods Mol Biol. 2014;1195:133-44
pubmed: 24504930
J Biol Chem. 2013 Dec 13;288(50):35812-23
pubmed: 24189069
Front Cell Dev Biol. 2021 Feb 04;8:618296
pubmed: 33614627
Elife. 2021 Apr 23;10:
pubmed: 33890572
Cell Res. 2008 Feb;18(2):290-301
pubmed: 18227861
J Lipid Res. 2013 Aug;54(8):2174-2184
pubmed: 23733886
FEBS J. 2020 Sep;287(17):3664-3671
pubmed: 32428379
Science. 1986 Apr 4;232(4746):34-47
pubmed: 3513311
Molecules. 2016 Dec 20;21(12):
pubmed: 27999408
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Stem Cell. 2021 Jul 1;28(7):1205-1220.e7
pubmed: 34022129
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Mol Biol Cell. 1993 Dec;4(12):1251-66
pubmed: 8167408
Front Immunol. 2021 Dec 16;12:796855
pubmed: 34975904
Cell Res. 2021 Feb;31(2):126-140
pubmed: 33420426
Cell Commun Signal. 2015 Apr 10;13:24
pubmed: 25889964
Oncotarget. 2017 Oct 19;8(61):103985-103995
pubmed: 29262615
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731
pubmed: 32226290
Immunity. 2013 Jan 24;38(1):106-18
pubmed: 23273843
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Biomolecules. 2020 Aug 21;10(9):
pubmed: 32825713
Cell Res. 2020 Nov;30(11):1043-1045
pubmed: 32811977
J Leukoc Biol. 2010 Dec;88(6):1081-7
pubmed: 20699362
Br J Pharmacol. 2021 Aug;178(16):3220-3234
pubmed: 32698250
Mol Vis. 2017 Mar 05;23:60-89
pubmed: 28356702
Nat Metab. 2020 Dec;2(12):1391-1400
pubmed: 33244168
Antivir Chem Chemother. 1998 Nov;9(6):491-6
pubmed: 9865387
Mol Biol Evol. 2005 May;22(5):1208-22
pubmed: 15703242
Exp Eye Res. 1996 Feb;62(2):155-69
pubmed: 8698076
Int J Mol Sci. 2021 Jun 17;22(12):
pubmed: 34204305
Lipids Health Dis. 2016 Jul 12;15(1):115
pubmed: 27405337
Front Med (Lausanne). 2021 Jan 05;7:620412
pubmed: 33469546
J Biol Chem. 1996 Jul 5;271(27):16026-34
pubmed: 8663188
J Lipid Res. 2014 Aug;55(8):1609-21
pubmed: 24664998
Viruses. 2020 Jul 06;12(7):
pubmed: 32640529
Lancet Infect Dis. 2023 Jun;23(6):655-656
pubmed: 37148902
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35078919
Chem Biol. 2010 Dec 22;17(12):1344-55
pubmed: 21168770
Virol J. 2021 Feb 27;18(1):46
pubmed: 33639976
Cells. 2021 Jun 07;10(6):
pubmed: 34200372
PLoS Genet. 2012;8(7):e1002764
pubmed: 22807683
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2541-6
pubmed: 22936343
Nat Rev Immunol. 2020 Oct;20(10):592
pubmed: 32826975
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
PLoS One. 2020 Oct 15;15(10):e0240659
pubmed: 33057430
Traffic. 2015 Jun;16(6):635-54
pubmed: 25693808
Curr Opin Pharmacol. 2020 Aug;53:18-26
pubmed: 32361182
Cells. 2021 Jul 17;10(7):
pubmed: 34359983
Sci Transl Med. 2022 Dec 7;14(674):eabm9151
pubmed: 36137009
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4239-44
pubmed: 22371602
Front Microbiol. 2020 Aug 11;11:1821
pubmed: 32849425
Obesity (Silver Spring). 2020 Dec;28(12):2357-2367
pubmed: 33043593
Cell. 2021 Apr 15;184(8):2212-2228.e12
pubmed: 33713620
J Virol. 2020 Jul 30;94(16):
pubmed: 32493827
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Eur J Biochem. 1989 Dec 8;186(1-2):17-22
pubmed: 2598927
Redox Biol. 2018 Oct;19:318-330
pubmed: 30212801
PLoS One. 2018 Jul 2;13(7):e0199012
pubmed: 29965997
Mol Cell Biochem. 2022 Mar;477(3):849-864
pubmed: 35066705
Nat Rev Genet. 2007 Nov;8(11):857-68
pubmed: 17943193
Nat Rev Immunol. 2022 Mar;22(3):144
pubmed: 35082449
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Curr Biol. 2000 Nov 16;10(22):R823-5
pubmed: 11102822

Auteurs

Sheetal Uppal (S)

Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Olga Postnikova (O)

Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Rafael Villasmil (R)

Flow Cytometry Core Facility, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Igor B Rogozin (IB)

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA.

Alexander V Bocharov (AV)

Clinical Center, National Institutes of Health, Bethesda, MD 20894, USA.

Thomas L Eggerman (TL)

Clinical Center, National Institutes of Health, Bethesda, MD 20894, USA.
National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Eugenia Poliakov (E)

Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

T Michael Redmond (TM)

Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH